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Abstract 
Matrix metalloproteinase-1 MMP1 has attracted interest in cancer research, owing to its role in tumour 
progression. The current study aimed to evaluate the expression of matrix metalloproteinase-1 MMP1in human 
breast cancer women patients. An immunohistochemical study was performed using tumours from 41 breast 
cancer patients, with specific antibodies against, MMP-1The results indicated that expression was related to 
tumour size, histological grade, Regarding the malignant lesions, the age incidence in six cases below forty 
years were (19.37%). 23 patients (41.93%) were between (40-49) years. four cases (12.90%) were between (50-
59) years old and eight cases were above (60) years old about (25.8%)  matrix metalloproteinase-1 MMP1 is 
expressed in the cytoplasim of the cells. Negative expression scored (0) were observed in 25 out of 31samples 
(48.3%), while score (+) found in 5 out of 31samples (16.12%), score (++) found in 2 out of 31samples (6.4%) 
and score (+++) found in 9 out of 31samples (29%). While the benign breast lesions revealed positive 
expression in (5.26%) of lesions. Breast carcinomas in present work indicated overexpression strong by MMP1 
marker.  
Keywords: breast carcinoma; matrix metalloproteinase-1 MMP1; Immunohistochemical staining; Iraqi women 
patients. 
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1. Introduction 
the most common risk factor female malignancy in Iraq and worldwide was Breast cancer disease, recorded 
nearly million cases annually [1]. Breast tumors arise from terminal ductal lobular units, and divided in two 
phenotype first ductal carcinoma and the second lobular neoplasia [2]. Breast cancer disease based in the history 
of the family and the invasion and virulence based on molecular base, and also immunohistochemichal like 
MMP 1 maker [3,4]. Iraqi Cancer Registry recorded reports  summarized in : first the commonest type of 
malignancy in females and there is a general trend towards an increase in the frequency and the second  the 
incidence of breast cancer in younger age group. The  environment of the cell represented the site of tumor 
exists, which included extracellular matrix (ECM), immune cells, fibroblasts, surrounding blood vessels, 
signaling molecules and other cells in the tissue. There's closely relationship between microenvironment and 
tumor when tumors can effects in the microenvironment through extracellular signals releasing, peripheral 
immune tolerance inducing, and through tumor angiogenesis promoting [5]. The microenvironment of tumor 
cell treated angiogenesis through interfere with the required for cell recruitment and vascular construction 
signaling pathways. matrix metalloproteinase-1 (MMP1) have a correlation with cell metastasis and also 
recruited for angiogenesis under hypoxic conditions [6]  this present work aimed to detection of matrix 
metalloproteinase-1 (MMP1) expression using immunohistochemichal teqnique (IHC). 
2. Methods 
Immunohistochemichal IHC staining method and evaluation of Immunohistochemistry results 
1. Slide baking: the slides were placed in a 45° and  Deparaffinization: in xylene for 15 minutes two times at 
room temperature. 
3. Rehydration: the slides were immersed sequentially in the following solutions at room temperature starting 
with: 
-Twice in absolute ethanol for 5 minutes. 
-95  % ethanol for 5 minutes. 
-90   % ethanol for 5 minutes. 
-80   % ethanol for 5 minutes. 
-70 % ethanol for 5 minutes. 
-Distilled water for 5 minutes. 
4. Enough drops of hydrogen peroxide block were added to slides  
5. Enough drops of protein block were added to slides and incubated at 37ºC for 10 minutes.  
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6. Diluted primary antibody was applied to each slide,  
7. Enough drops of secondary antibody (link antibody yellow drops) reagent were added and incubated in humid 
chamber for 20 minutes at37ºC. 
The Positive reading result  was appeared when the cytoplasmic pigmentation cells display a brown staining, 
while when cytoplasmic pigmentation absence of immunostaining the results for the cases consider negative 
reading. Cut off values for all the antibodies used in the study were done with the help of a pathologist. The 
scoring of the immunostaining  was done under light microscope to evaluate the percentage of antibodies 
immunostaining; positively stained cells were counted at 5 representative fields (400X). 
Immunohistochemical scoring of matrix metalloproteinase-1 MMP1 Anti –MMP1 antibody [ab3203] 
matrix metalloproteinase-1 MMP1 [ab3203] over expression(positive) was seen in the cytoplasim of the  
subjected cell of breast cancer and in contrl benign cells and the scoring of positive tumor cell was considered as 
follows [7]: the percentage value pf intensity 0 =0-10% , 1+ =10-25%,2+ =25-50%,3+  =more than 50%. 
3. Statistical Analysis 
The values of posative expression of the studied marker parameters were represented by (mean ± standard 
error), and person correlation using version 7.5 of computer program SAS. The value of probability ≥ 0.05 and 
0.001[8]. 
4. Results and Discussion  
Clinicopathological features show total of newly diagnosed, 41 Iraqi females patients with breast cancer had a 
mean age (42 ±7.35) years with a range of 33 to 72 years compared with 19 patients control (with benign breast 
lesions their mean age were (29.21 ±3.54) years with a range of (19 to 49 years). Regarding the malignant 
lesions, the age incidence in six cases below forty years were (19.37%).  
13 patients (41.93%) were between (40-49) years. four cases (12.90%) were between (50-59) years old and eight 
cases were above (60) years old about (25.8%) as show in table (1).  
In Benign Breast lesions, 16 cases (84.21%) were less than 40 years; 3 cases (15.7%) were 40-49 years and no 
cases aged more than 49 years, table (1). 
The invasive breast carcinomas NOS type were graded according to the Nottingham histological grading (WHO 
and modified Bloom-Richardson grading system), 21 (67.7%) cases were grade II and 10 (32.2%) cases were 
grade III.  
Table (1) reveals the stages of BC for 41 patients according to TNM system, 14 cases (45. 1%) were stages (I 
and II); 15 cases (48.3%) were stage III and 2 cases (6.45%) were stage IV. 
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Table 1: Clinicopathological characteristics of the breast cancer patients 
Parameter Malignant breast (41) 
Age (Years) No. % 
<40 6 19.37 
40-49 13 41.93 
50-59 4 12.90 
≥60 8 25.80 
Tumor Type 
Invasive ductal carcinoma 31 100 
Histological grade 
Grade II 21 67.7 
Grade III 10 32.2 
Staging system 
Stages I and II 14 45.1 
Stage III 15 48.3 
Stage IV 2 6.4 
 
The presented results on Iraqi patients revealed that a high age frequency of cancer occurred between (40-49) 
years old (41.93%). This is due to causes such as environmental factors, the nutrition, low exercise, poor health 
education. The high dose exposure of depleted uranium during the war may be considering the most causative 
reason for breast cancer risk increasing in the Iraqi community. Also theirs no attention from the national 
screening programs for early diagnosis of breast cancer patients in all the country .Our results agreed with many 
studies in Iraq performed on breast cancer and revealed that the peak of age frequency in the Iraqi breast cancer 
patients was 44.5 years, and that 76.8% were under 50 years [9], showed that a mean age of the 48.7 years and 
that 32.6% of the cancer patients were in the peak age frequency of 40-49 years. 
The middle aged and elderly women have a risk of breast cancer and consider higher in this ages when 
compared with young women. Thers strong correlation between age and breast cancer disease [10]. Breast 
cancer affects up to one in eight women in developed countries with a median age of 61 years at diagnosis. 
Approximately 2% of breast cancers occur in young women between 20 and 34 years of age and 11% between 
35 and 44 years of age [11]. In USA during 2002-2006, 50% of women who developed breast cancer were at the 
age 61 or younger at the time of diagnosis [12] Although grading system could be variable because of its 
subjective nature, still it is one of the important parameter regarding prognosis evaluation [13]. Grading of the 
malignant cases was assessed according to the Nottingham Modification of the Bloom-Richardson system [14] . 
In this study, 67.7% were moderately differentiated (grade I) and 32.2% were poorly differentiated (grade III). 
In our study immunohistochemical techniques were used to detect the protein expression of matrix 
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metalloproteinase-1 MMP1 in the Iraqi breast tissues, among breast cancer groups and benign tumor groups 
IHC expression of matrix metalloproteinase-1 MMP1 
Matrix metalloproteinase-1 MMP1 is expressed in the cytoplasim of the cells, so it differs from the other 
studied markers which were nucleus expressed markers. Negative expression scored (0) were observed in 15 
out of 41samples (48.3%), while score (+) found in 5 out of 31samples (16.12%), score (++) found in 2 out of 
31samples (6.4%) and score (+++) found in 9 out of 31samples (29%). While the benign breast lesions 
revealed positive expression in (5.26%) of lesions as in Table (2). Statistical analysis of the matrix 
metalloproteinase-1 MMP1expression showed high significant difference between the malignant breast 
samples expression and the benign samples (P <0.001).  The figure (1).show the expression of matrix 
metalloproteinase-1 MMP1 in the membrane of ductal carcinoma stained by IHC (Brown stained membrane 
which indicates the positive expression matrix metalloproteinase-1 MMP1 and the negative expression 
showed no nucleus staining). 
Table 2: Immunohistochemical of matrix metalloproteinase-1 MMP1 Expression in ductal carcinoma 
              Score 
group 
0 + ++ +++ Total positive 
Benign 18 (94.73%)     
A 
0 (0%)        B 0 (0%)         
B 
1 (5.26%)    C  1 (5.26%) 
from (19) 
Malignant 15 (48.38%) 
AB 
5 (16.12%) C 2 (6.45%)        
C 
9 (29.03%) C 16 (51.6%) 
from(31) 
*** P <0.001 
Difference letters mean presence of significant difference. 
Same letters mean there is no significant difference. 
matrix metalloproteinase-1 MMP1 marker represented as putative cancer stem cells marker in breast cancer, the 
value of MMP1expression mean that theirs important roles to MMP1 marker the in microenvironment of the 
tumor related to breast cancer. The results of our present study, represented by: 
1- Evaluation of matrix metalloproteinase-1 MMP1 expression in the subjected studied cased of human 
breast carsenoma. 
2- clinicopathological correlations with the studied markers determination.  
   Recent evidence has suggested that breast cancer originates from CSCs, which strongly express adhesion 
molecule matrix metalloproteinase-1 MMP1 [15]. The cell adhesion molecule matrix metalloproteinase-1 
MMP1 is consider the as receptor for cell surface for glycosaminoglycan hyaluronic (HA)extracellular matrix, 
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these activities of studied immune marker lead to different important biological events through interactions 
between HA and matrix metalloproteinase-1 MMP1 these interaction lead to activation, inflammatory reactions, 
,tumor dissemination embryogenesis, hematopoiesis and lymphocyte homing [16]. 
 
 
Figure 1: Immunohistochemical staining in breast cancer sections. immunostaining by peroxidase/ DAB 
(brown) counterstained with heamatoxyline (blue) , (A) positive matrix metalloproteinase-1 MMP1 
expression(400X),(B) negative (no expression) for matrix metalloproteinase-1 MMP1 (400X). 
Our results relatively agreed with the results obtained from Wang and his colleagues (2011) who study the 
expression of matrix metalloproteinase-1 MMP1 in invasive ductal carcinoma which expressed in (43.6%). And 
also they completely agree with [17] who revealed the matrix metalloproteinase-1 MMP1 marker was 
commonly expressed among primary breast carcinomas (51.2% of positive cases). 
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the important of matrix metalloproteinase-1 MMP1 marker expression lead to understanding the most important 
points in treatment of Cancer, therapeutic target, focus on the tumor microenvironment and non-malignant cells 
are more stable in genetic manner and have a phenotypes not evolve into drug resistant. The  microenvironment 
of the tumor tissue appeared that theirs contribution lead to development of tumor. [18]. While the 
microenvironment of normal cell produce signaling lead to malignant cell growth inhibition, the cell 
proliferation in the tumor microenvironment support against development of cancer in synergistic manner 
[19,20] . 
5. Conclusion 
Matrix metalloproteinase-1 MMP1 over expression in present studied cases lead to understand the importance of 
an altered microenvironment in tumorigenesis and nature of the molecular alterations underlying in treatment 
and suggesting molecular detection to the studied cases for more understanding[20].  
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